322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

In this discussion, Matt Herper, a STAT reporter focused on cancer immunotherapy, joins Bob Duggan, co-CEO of Summit, to delve into recent turbulence in cancer treatments. They explore a groundbreaking drug that outperforms Merck's Keytruda in lung cancer trials. The talk shifts to the complexities faced by Moderna, balancing vaccine production with drug development despite having ample cash reserves. Finally, they examine ethical concerns surrounding obesity drugs tested in children and their implications for future treatments.